BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21190824)

  • 1. A mouse model for nonalcoholic steatohepatitis.
    Sundaresan S; Vijayagopal P; Mills N; Imrhan V; Prasad C
    J Nutr Biochem; 2011 Oct; 22(10):979-84. PubMed ID: 21190824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.
    Asano T; Watanabe K; Kubota N; Gunji T; Omata M; Kadowaki T; Ohnishi S
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1669-76. PubMed ID: 19788607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice.
    Kubota N; Kado S; Kano M; Masuoka N; Nagata Y; Kobayashi T; Miyazaki K; Ishikawa F
    Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):422-30. PubMed ID: 23611112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis.
    Gäbele E; Dostert K; Dorn C; Patsenker E; Stickel F; Hellerbrand C
    Alcohol Clin Exp Res; 2011 Jul; 35(7):1361-7. PubMed ID: 21463337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.
    Lo L; McLennan SV; Williams PF; Bonner J; Chowdhury S; McCaughan GW; Gorrell MD; Yue DK; Twigg SM
    J Hepatol; 2011 Aug; 55(2):435-44. PubMed ID: 21184785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
    Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
    Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes.
    Larter CZ; Yeh MM; Williams J; Bell-Anderson KS; Farrell GC
    J Hepatol; 2008 Sep; 49(3):407-16. PubMed ID: 18534710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
    Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency.
    Kirsch R; Clarkson V; Verdonk RC; Marais AD; Shephard EG; Ryffel B; de la M Hall P
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):174-82. PubMed ID: 16706830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation.
    Kirovski G; Dorn C; Huber H; Moleda L; Niessen C; Wobser H; Schacherer D; Buechler C; Wiest R; Hellerbrand C
    Exp Mol Pathol; 2011 Dec; 91(3):780-3. PubMed ID: 21855538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
    Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model.
    Kamada Y; Matsumoto H; Tamura S; Fukushima J; Kiso S; Fukui K; Igura T; Maeda N; Kihara S; Funahashi T; Matsuzawa Y; Shimomura I; Hayashi N
    J Hepatol; 2007 Oct; 47(4):556-64. PubMed ID: 17459514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
    Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
    Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
    Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
    Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling.
    Imajo K; Fujita K; Yoneda M; Nozaki Y; Ogawa Y; Shinohara Y; Kato S; Mawatari H; Shibata W; Kitani H; Ikejima K; Kirikoshi H; Nakajima N; Saito S; Maeyama S; Watanabe S; Wada K; Nakajima A
    Cell Metab; 2012 Jul; 16(1):44-54. PubMed ID: 22768838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
    Kathirvel E; Morgan K; French SW; Morgan TR
    Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.